<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR18">
 <label>18.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Juric</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Janku</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Rod√≥n</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Burris</surname>
    <given-names>HA</given-names>
   </name>
   <name>
    <surname>Mayer</surname>
    <given-names>IA</given-names>
   </name>
   <name>
    <surname>Schuler</surname>
    <given-names>M</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer. A phase 1b Clin trial</article-title>
  <source>JAMA Oncol</source>
  <year>2019</year>
  <volume>5</volume>
  <fpage>e184475.</fpage>
  <pub-id pub-id-type="doi">10.1001/jamaoncol.2018.4475</pub-id>
  <?supplied-pmid 30543347?>
  <pub-id pub-id-type="pmid">30543347</pub-id>
 </element-citation>
</ref>
